RT Journal Article
SR Electronic
T1 Safety, Immunologic Effects and Clinical Response in a Phase I Trial of Umbilical Cord Mesenchymal Stromal Cells in Patients with Treatment Refractory Systemic Lupus Erythematosus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.31.22273106
DO 10.1101/2022.03.31.22273106
A1 Kamen, Diane
A1 Wallace, Caroline
A1 Li, Zihai
A1 Wyatt, Megan
A1 Paulos, Crystal
A1 Wei, Chungwen
A1 Wang, Hongjun
A1 Sanz, Inaki
A1 Wolf, Bethany J
A1 Nietert, Paul J
A1 Robinson, Angela
A1 Gilkeson, Gary
YR 2022
UL http://medrxiv.org/content/early/2022/04/03/2022.03.31.22273106.abstract
AB Background Reports of clinical improvement following mesenchymal stromal cell (MSC) infusions in refractory lupus patients at a single center in China led us to perform an explorative Phase I trial of umbilical cord derived MSCs in patients refractory to six months of immunosuppressive therapy.Methods Six women with a SLEDAI>6, having failed standard of care therapy, received one IV infusion of 1×106 MSCs/kg of body weight. They maintained their current immunosuppressives, but their physician was allowed to adjust corticosteroids initially for symptom management. The clinical endpoint was an SRI of 4 with no new BILAG As and no increase in Physician Global Assessment score of >0.3 with tapering of prednisone to 10mg or less by 20 weeks.Results Of 6 patients, 5 (83.3%; 95% CI = 35.9% to 99.6%) achieved the clinical endpoint of an SRI of 4. Adverse events were minimal. Mechanistic studies revealed significant reductions in CD27IgD negative B cells, switched memory B cells and activated naïve B cells with increased transitional B cells in the 5 patients who met the endpoint. There was a trend towards decreased autoantibody levels in specific patients. One patient had an increase in their Helios+Treg cells, but no other significant T cell changes were noted. GARP-TGFβ complexes were significantly increased following the MSC infusions. The B cell changes and the GARP-TGFβ increase were significantly correlated with SLEDAI scores.Conclusion This pilot trial suggests that UC MSC infusions are safe and may have efficacy in lupus. The B cell and GARP-TGFβ changes provide insight into mechanisms by which MSCs may impact disease.Trial Registration NCT03171194Funding This study was funded by a grant from the Lupus Foundation of America and NIH UL1 RR029882Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIND 16377, NCT03171194Clinical Protocols https://www.MUSC/lupus.edu Funding StatementThis study was funded by the Lupus Foundation of America and NIH grant NIH UL1 RR029882Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB2 of the Medical University of South Carolina gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://www.MUSC/lupus.edu